CN115153031A - Nutritional composition for infant formula - Google Patents
Nutritional composition for infant formula Download PDFInfo
- Publication number
- CN115153031A CN115153031A CN202110356483.9A CN202110356483A CN115153031A CN 115153031 A CN115153031 A CN 115153031A CN 202110356483 A CN202110356483 A CN 202110356483A CN 115153031 A CN115153031 A CN 115153031A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- compound
- content
- nutritional composition
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 47
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 74
- 235000010755 mineral Nutrition 0.000 claims abstract description 74
- 239000011707 mineral Substances 0.000 claims abstract description 74
- 229940088594 vitamin Drugs 0.000 claims abstract description 67
- 229930003231 vitamin Natural products 0.000 claims abstract description 67
- 235000013343 vitamin Nutrition 0.000 claims abstract description 67
- 239000011782 vitamin Substances 0.000 claims abstract description 67
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 63
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims abstract description 58
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 53
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 34
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 32
- 239000011709 vitamin E Substances 0.000 claims abstract description 32
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 31
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 31
- 229940046009 vitamin E Drugs 0.000 claims abstract description 31
- 229940045997 vitamin a Drugs 0.000 claims abstract description 30
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 29
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 29
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 29
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 29
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 29
- 229940108325 retinyl palmitate Drugs 0.000 claims abstract description 29
- 235000019172 retinyl palmitate Nutrition 0.000 claims abstract description 29
- 239000011769 retinyl palmitate Substances 0.000 claims abstract description 29
- 229960000344 thiamine hydrochloride Drugs 0.000 claims abstract description 29
- 239000011747 thiamine hydrochloride Substances 0.000 claims abstract description 29
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 29
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims abstract description 29
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 29
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 29
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 29
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 28
- 239000011719 vitamin A Substances 0.000 claims abstract description 28
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 27
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 27
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 27
- 229910052742 iron Inorganic materials 0.000 claims abstract description 27
- 239000011701 zinc Substances 0.000 claims abstract description 26
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 26
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000016804 zinc Nutrition 0.000 claims abstract description 24
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 18
- -1 compound vitamin Chemical class 0.000 claims description 22
- 239000011575 calcium Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 17
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 17
- 239000001354 calcium citrate Substances 0.000 claims description 17
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 14
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 5
- 235000002414 D-alpha-tocopherylacetate Nutrition 0.000 claims description 3
- 239000011740 D-alpha-tocopherylacetate Substances 0.000 claims description 3
- 229940039770 d-alpha-tocopheryl acetate Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 abstract description 23
- 238000010521 absorption reaction Methods 0.000 abstract description 21
- 235000013305 food Nutrition 0.000 abstract description 21
- 230000036039 immunity Effects 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 11
- 230000002708 enhancing effect Effects 0.000 abstract description 9
- 241000700159 Rattus Species 0.000 description 30
- 239000000843 powder Substances 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 22
- 230000009102 absorption Effects 0.000 description 20
- 235000015097 nutrients Nutrition 0.000 description 19
- 235000019156 vitamin B Nutrition 0.000 description 19
- 239000011720 vitamin B Substances 0.000 description 19
- 229930003270 Vitamin B Natural products 0.000 description 18
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 16
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010046377 Whey Proteins Proteins 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 9
- 229960001763 zinc sulfate Drugs 0.000 description 9
- 229910000368 zinc sulfate Inorganic materials 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 8
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 8
- 238000008157 ELISA kit Methods 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 229940028885 interleukin-4 Drugs 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 229960000342 retinol acetate Drugs 0.000 description 8
- 235000019173 retinyl acetate Nutrition 0.000 description 8
- 239000011770 retinyl acetate Substances 0.000 description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 8
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 229940027941 immunoglobulin g Drugs 0.000 description 7
- 229940088592 immunologic factor Drugs 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000012041 food component Nutrition 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 210000001694 thigh bone Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 235000021119 whey protein Nutrition 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000000367 immunologic factor Substances 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 239000011706 ferric diphosphate Substances 0.000 description 4
- 235000007144 ferric diphosphate Nutrition 0.000 description 4
- 229940036404 ferric pyrophosphate Drugs 0.000 description 4
- 239000011790 ferrous sulphate Substances 0.000 description 4
- 235000003891 ferrous sulphate Nutrition 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229940099472 immunoglobulin a Drugs 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 229960003080 taurine Drugs 0.000 description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000019743 Choline chloride Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960003178 choline chloride Drugs 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000000120 microwave digestion Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 235000000638 D-biotin Nutrition 0.000 description 2
- 239000011665 D-biotin Substances 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229910002056 binary alloy Inorganic materials 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 2
- 239000001230 potassium iodate Substances 0.000 description 2
- 235000006666 potassium iodate Nutrition 0.000 description 2
- 229940093930 potassium iodate Drugs 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 235000012711 vitamin K3 Nutrition 0.000 description 2
- 239000011652 vitamin K3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 150000003752 zinc compounds Chemical class 0.000 description 2
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 101001043830 Rattus norvegicus Interleukin-2 Proteins 0.000 description 1
- 101000960939 Rattus norvegicus Interleukin-4 Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000000705 flame atomic absorption spectrometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a nutritional composition for infant formula food, and specifically the nutritional composition contains compound vitamins and compound mineral substances, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; the iron and the zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate. The nutritional composition has the functions of obviously enhancing the immunity of the organism and promoting digestion and absorption.
Description
Technical Field
The invention belongs to the field of food biotechnology. In particular, the present invention relates to a nutritional composition for infant formulas, and to a formula comprising said nutritional composition.
Background
The infant formula food is a preferred food for infants without or with insufficient breast milk, and the content, digestibility and physiological function of each nutrient component of the infant formula food have important significance for the normal growth and development of the infants.
Iron is a micronutrient necessary for cells, is mainly involved in oxygen transport in vivo and tissue respiratory chain transmission, is involved in hemoglobin, myoglobin and cytochrome, and is an important element for maintaining normal hematopoiesis of infants.
Zinc is involved in the composition of various hormones, vitamins, proteins and enzymes, and in the catalytic, structural and regulatory functions of the body. Zinc plays an important role in the growth and development process of infants, is an activator of in vivo enzyme, can improve the immunologic function of the infant body, maintain the integrity of a cell membrane structure, and simultaneously has a protective effect on skin and eyesight.
Calcium is a main component of bones and teeth of infants, is involved in the activation of various enzymes in vivo and the maintenance of excitability of nerves and muscles and the transmission of nerve impulses, is also involved in blood coagulation, hormone secretion, the maintenance of acid-base balance of body fluid and the regulation of normal physiological functions of cells, and is involved in the regulation of the integrity and permeability of biological membranes.
Vitamin A plays a vital role in many life processes of the body, has wide physiological functions including participation in visual processes, cell proliferation and differentiation, intercellular information communication, organ and tissue growth, reproduction and immune system functions, and can influence the growth and development of infants, reproduction functions, immune functions, hematopoietic functions and the completeness of skin mucosa.
The main physiological function of vitamin E is to act as a strong antioxidant, protecting cell membranes from peroxidation damage; vitamin E is stored as a lipophilic compound in circulating lipoproteins, cell membranes and adipose tissue; reacting with free radicals and molecular oxygen to protect polyunsaturated fatty acids and lipoproteins from peroxidation; meanwhile, vitamin E also maintains fertility, is very important in the early stages of life, and participates in the development from the conception process to the postnatal period.
Vitamin B 1 In addition to playing an important role as a coenzymeBesides the functions, the food also plays a significant role in maintaining normal physiological functions of nerves and muscles, particularly cardiac muscle, maintaining normal appetite, gastrointestinal peristalsis, secretion of digestive juice and the like.
At present, in the existing infant formula milk powder, vitamin A mostly uses retinyl acetate, vitamin E mostly uses dl-alpha-tocopheryl acetate, and vitamin B 1 Thiamine nitrate is mostly used, ferrous sulfate is mostly used for iron, zinc sulfate is mostly used for zinc, and calcium carbonate is mostly used for calcium. However, the nutritional components have some disadvantages and shortcomings, for example, ferrous sulfate has a low bioavailability and severe irritation to intestines and stomach of infants although the cost performance is high, and zinc sulfate and calcium carbonate have low bioavailability. Compared with the existing nutrient combination, the nutrient combination has the functions of obviously enhancing the immunity of the organism and promoting the digestion and absorption.
Disclosure of Invention
One of the purposes of the invention is to provide a nutritional composition for infant formula food, which contains compound vitamins and compound minerals, and has the functions of obviously enhancing the immunity of the organism and promoting digestion and absorption.
In one aspect, the present invention provides a nutritional composition for infant formula comprising a vitamin complex comprising vitamin a, vitamin E and vitamin B and a mineral complex comprising vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; the iron and the zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate.
In a specific embodiment of this aspect, the present invention provides the above nutritional composition, wherein the vitamin complex comprises retinyl palmitate in an amount of about 1.92 to about 3.52%, d-alpha-tocopherol acetate in an amount of about 7.61 to about 13.32%, and thiamine hydrochloride in an amount of about 0.34 to about 0.55%; preferably, the vitamin complex contains retinyl palmitate about 2.09-3.32%, d-alpha-tocopherol acetate about 8.29-12.54%, and thiamine hydrochloride about 0.37-0.51%.
In another specific embodiment of this aspect, the present invention provides the nutritional composition as described above, wherein the compound mineral has a ferrous gluconate content of about 13.91 to 44.35% and a zinc gluconate content of about 8.25 to 16.62%; preferably, the compound mineral contains ferrous gluconate about 15.13-41.76% and zinc gluconate about 8.97-15.65%.
In another specific embodiment of this aspect, the present invention provides the above nutritional composition, wherein the calcium is provided by calcium citrate.
In another specific embodiment of this aspect, the present invention provides the above nutritional composition, wherein the weight ratio of the calcium citrate to the compound mineral is 1.33 to 3.33.
It is another object of the present invention to provide an infant formula comprising the above nutritional composition.
In a specific embodiment of this aspect, the present invention provides the above infant formula wherein the level of compound vitamin is from about 0.1 to 1%, preferably from about 0.3 to 0.5%; the content of the compound mineral is about 0.1-1%, preferably about 0.3-0.5%.
It is another object of the present invention to provide the use of the above nutritional composition for the preparation of infant formulas, wherein the infant formulas are milk and dairy products.
In a specific embodiment of this aspect, the invention provides the above use wherein the amount of the vitamin complex in the infant formula is from about 0.1 to 1%, preferably from about 0.3 to 0.5%; the content of the compound mineral is about 0.1-1%, preferably about 0.3-0.5%.
In another specific embodiment of this aspect, the present invention provides the above use wherein the vitamin complex has a retinyl palmitate content of about 1.92 to 3.52%, tocopherol d- α -acetate content of about 7.61 to 13.32%, thiamine hydrochloride content of about 0.34 to 0.55%; preferably, the compound vitamin contains retinyl palmitate about 2.09-3.32%, d-alpha-tocopherol acetate about 8.29-12.54%, and thiamine hydrochloride about 0.37-0.51%;
wherein the content of the ferrous gluconate in the compound mineral is about 13.91 to 44.35 percent, and the content of the zinc gluconate is about 8.25 to 16.62 percent; preferably, the compound mineral contains ferrous gluconate about 15.13-41.76% and zinc gluconate about 8.97-15.65%.
The invention strictly follows the 'health food function evaluation standard', and evaluates the effects of the nutrient composition containing the compound vitamin and the compound mineral substance on the aspects of enhancing the immunity of the organism and promoting the digestion and absorption. Animal experiments prove that the nutritional composition is prepared by selecting and scientifically matching special vitamins and mineral components, and trace addition can obviously enhance the immunity of the organism, reduce the occurrence risk of various diseases, promote digestion and absorption, particularly to vitamin A, vitamin E and vitamin B 1 And the digestion and absorption of iron, zinc and calcium.
After long-term research and numerous experiments, we have surprisingly found that particular vitamin A (retinyl palmitate), vitamin E (d-alpha-tocopheryl acetate) and vitamin B are selected 1 (thiamine hydrochloride) and iron (ferrous gluconate), zinc (zinc gluconate) and calcium (calcium citrate) as opposed to vitamin a (retinyl acetate), vitamin E (dl-alpha-tocopherol acetate) and vitamin B (vitamin a) commonly used in existing infant formulas 1 The (thiamine nitrate), iron (ferrous sulfate), zinc (zinc sulfate) and calcium (calcium carbonate) have the effects of obviously improving the immunity of the organism and promoting digestion and absorption, and simultaneously overcome the disadvantages and the defects of the existing infant formula food, which is a technical effect that cannot be expected from the prior art by technical personnel in the field and has great significance for improving the existing infant formula food.
Therefore, aiming at the disadvantages and deficiencies of the existing infant formula food, a nutritional composition for enhancing the immunity of the organism and promoting the digestion and absorption is developed, and contains the compound vitamin and the compound mineral. The infant formula food capable of enhancing the immunity of the organism and promoting digestion and absorption is prepared, and the market demand for the nutritional components is met.
Detailed description of the preferred embodiments
Definition of
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, but in the event of conflict, the definitions set forth herein shall control.
As used in the specification and in the claims, the singular form of "a", "an", and "the" include plural referents unless the context clearly dictates otherwise.
Unless otherwise specified, the percentages (%) in this specification are all weight percentages (% by weight).
All numbers or expressions referring to quantities of ingredients, process conditions, etc. used in the specification and claims are to be understood as modified in all instances by the term "about". The term "about" when referring to a quantity or a numerical range means that the quantity or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the quantity or numerical range may vary, for example, between ± 5 of the quantity or numerical range.
All ranges directed to the same component or property are inclusive of the endpoints, and the endpoints are independently combinable. Because these ranges are continuous, they include every value between the minimum and maximum values. It should also be understood that any numerical range recited herein is intended to include all sub-ranges within that range.
When the present invention is directed to a physical property, such as molecular weight, or to a range of chemical properties, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "comprising" (and related terms such as "comprising" or "including" or "having" or "including") includes embodiments that are, for example, any combination of materials, components, methods, or processes that "consist of or" consist essentially of the recited features.
As used in this specification and claims, "and/or" should be understood to mean "either or both" of the associated components, i.e., the components may be present in combination in some instances and separately in other instances. A plurality of components listed with "and/or" should be understood in the same manner as "one or more" associated components. In addition to the "and/or" clause-specific components, other components may optionally be present, whether related or unrelated to those specifically identified components. Thus, by way of non-limiting example, reference to "a and/or B," when used in connection with an open ended word such as "comprising," may refer in one embodiment to a alone (optionally including components other than B); in another embodiment, reference may be made to B alone (optionally including components other than a); in yet another embodiment, refers to a and B (optionally including other components), and the like.
It is to be understood that, unless explicitly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
The abbreviations used in the present invention have the usual meaning in the food, biological and chemical fields.
Nutritional composition
The nutritional composition of the present invention has (but is not limited to) the following functions: the health food can promote the improvement of the immune system of the organism, enhance the immunity of the organism, reduce the occurrence risk of various diseases and the like, and simultaneously can promote the digestion and absorption of nutrient components:
1) Enhancing the body immunity of infants: the infant nutritional composition can enhance the immunity of infants and improve the disease defense ability of infants, and is especially important for infants because the infant immune system is immature and lacks the cognition of health and diseases, so the disease defense ability is weaker than that of adults, and the resistance to unknown diseases is poorer, thereby the immune system is enhanced, and the resistance is provided.
2) Promoting the digestion and absorption of infants: the absorption degree of the infant on the nutrient components directly influences the development degree of each organ, the intelligence development condition, the physical health condition, the strength of the immunity of the organism and the like of the infant, so the digestion and absorption of each nutrient component have important significance on the healthy development of the infant. The nutritional composition is more suitable for infants to absorb and digest nutritional components, and has better bioavailability.
The invention relates to a nutritional composition for infant formula food, which contains compound vitamins and compound mineral substances, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; the iron and the zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate.
In particular, the combination of the above ingredients is important in achieving unexpected technical effects over the vitamins and minerals commonly used in existing infant formulas and is of great significance in improving existing infant formulas.
The specific content of each of the vitamins and minerals is as follows:
the content of the retinyl palmitate in the compound vitamin is about 1.92-3.52%, the content of the d-alpha-tocopheryl acetate is about 7.61-13.32%, and the content of the thiamine hydrochloride is about 0.34-0.55%; preferably, the vitamin complex contains retinyl palmitate in an amount of about 2.09-3.32%, d-alpha-tocopherol acetate in an amount of about 8.29-12.54%, and thiamine hydrochloride in an amount of about 0.37-0.51%.
The content of ferrous gluconate in the compound mineral is about 13.91 to 44.35 percent, and the content of zinc gluconate is about 8.25 to 16.62 percent; preferably, the compound mineral contains ferrous gluconate about 15.13-41.76% and zinc gluconate about 8.97-15.65%.
Illustratively, the nutritional compositions of the present invention comprise a combination of vitamins and a combination of minerals, the specific amounts of which are detailed below:
a nutritional composition for infant formula comprising a combination of vitamins and a combination of minerals, wherein per kg of the combination of vitamins comprises: 19.20 to 35.20g of retinyl palmitate (containing 25 ten thousand IU/g of vitamin A), 76.12 to 133.21g of d-alpha-tocopherol acetate (containing 46.98 percent of vitamin E) and thiamine hydrochloride (containing vitamin B) 1 74.7%) 3.43-5.46 g, cholecalciferol (containing vitamin)19.52 to 31.20g of D10 ten thousand IU/g, 4.16 to 7.68g of plant menadione (containing vitamin K5.0 percent) and riboflavin (containing vitamin B) 2 99%) 1.37-2.18 g, pyridoxine hydrochloride (containing vitamin B) 6 81%) 1.38-2.96 g, cyanocobalamin (containing vitamin B) 12 1.0 percent of 0.48 to 0.96g, 11.31 to 21.82g of nicotinamide (containing 99 percent of nicotinic acid), 2.40 to 6.60g of folic acid (containing 10 percent of folic acid), 10.11 to 16.55g of D-calcium pantothenate (containing 87 percent of pantothenic acid), 359.55 to 606.74g of L-sodium ascorbate (containing 89 percent of vitamin C), 4.00 to 8.40g of D-biotin (containing 1.0 percent of biotin), 136.00 to 216.00g of taurine (containing 100 percent of taurine), and 75.21 to 218.66g of auxiliary materials (lactose, maltodextrin or other food raw materials meeting the regulation requirements);
each kg of the compound mineral comprises: magnesium sulfate (14 percent of magnesium) 228.57-557.14 g, ferrous gluconate (11.5 percent of iron) 139.13-443.48 g, zinc gluconate (13 percent of zinc) 82.46-166.15 g, manganese sulfate (33 percent of manganese) 0.4-0.91 g, potassium iodate (0.76 percent of iodine) 10.53-63.16 g, copper sulfate (25 percent of copper) 3.20-9.84 g, sodium selenite (0.22 percent of selenium) 14.35-37.67 g, and auxiliary materials (lactose or maltodextrin or other food raw materials meeting the requirements of regulations) 107.60-161.41 g.
Wherein 1kg of compound mineral substance is required to be used together with 1.33-3.33 kg of calcium citrate.
Preferably, the nutritional composition for the infant formula comprises compound vitamins and compound minerals, wherein each kg of the compound vitamins comprises: 20.88 to 33.15g of retinyl palmitate (containing 25 ten thousand IU/g of vitamin A), 82.87 to 125.44g of d-alpha-tocopherol acetate (containing 46.98 percent of vitamin E), thiamine hydrochloride (containing vitamin B) 1 74.7 percent) 3.73 to 5.14g, cholecalciferol (vitamin D10 ten thousand IU/g) 21.23 to 29.38g, plant menadione (vitamin K5.0 percent) 4.52 to 7.23g, riboflavin (vitamin B) 2 99%) 1.49-2.05 g, pyridoxine hydrochloride (containing vitamin B) 6 81%) 1.50-2.79 g, cyanocobalamin (containing vitamin B) 12 1.0 percent of 0.52 to 0.90g, 12.30 to 20.55g of nicotinamide (containing 99 percent of nicotinic acid), 2.61 to 6.22g of folic acid (containing 10 percent of folic acid), 11 to 15.59g of D-calcium pantothenate (containing 87 percent of pantothenic acid), 391.01 to 571.35g of L-sodium ascorbate (containing 89 percent of vitamin C) and D-biotin (containing biotin 1).0%) 4.35-7.91 g, taurine (containing 100% taurine) 147.9-203.4 g, findings (lactose or maltodextrin or other food materials meeting the regulation requirement) 117.02-151.99 g;
each kg of the compound mineral comprises: 248.57-524.64 g of magnesium sulfate (containing 14% of magnesium), 151.3-417.61 g of ferrous gluconate (containing 11.5% of iron), 89.68-156.46 g of zinc gluconate (containing 13% of zinc), 0.44-0.86 g of manganese sulfate (containing 33% of manganese), 11.45-59.47 g of potassium iodate (containing 0.76% of iodine), 3.48-9.27 g of copper sulfate (containing 25% of copper), 15.61-35.47 g of sodium selenite (containing 0.22% of selenium), 152.15-358.12 g of auxiliary materials (lactose or maltodextrin or other food materials meeting the requirements of regulations);
wherein 1kg of compound mineral substance is required to be used together with 1.33-3.33 kg of calcium citrate.
Infant formula food
The nutritional composition can be added into infant formula food to prepare the infant formula food with specific functions (enhancing the immunity of the organism and promoting the digestion and absorption of nutritional components) of the nutritional composition, and compared with the existing infant formula food, the nutritional composition has obvious advantages and makes up the market demand for the nutritional components in the aspect.
It is particularly important that the infant formula contains specific contents of compound vitamins and compound minerals, so that the infant formula can achieve unexpected technical effects, wherein the specific contents are as described in detail below:
the content of the compound vitamin is about 0.1 to 1 percent, preferably about 0.3 to 0.5 percent; the content of the compound mineral is about 0.1-1%, preferably about 0.3-0.5%.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and do not limit the invention. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Nutritional component examples
Example 1
A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; iron and zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate;
wherein the content of the retinyl palmitate in the compound vitamin is 2.4 percent, the content of the d-alpha-tocopherol acetate is 11.1 percent, and the content of the thiamine hydrochloride is 0.46 percent; the content of ferrous gluconate in the compound mineral is 17.39%, and the content of zinc gluconate is 13.85%.
Wherein each portion of formulated mineral is required to be used with 1.33 portions of calcium citrate.
Example 2
A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; iron and zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate;
wherein the content of the retinyl palmitate in the compound vitamin is 2.93 percent, the content of the d-alpha-tocopherol acetate is 9.52 percent, and the content of the thiamine hydrochloride is 0.43 percent; the content of ferrous gluconate in the compound mineral is 22.61%, and the content of zinc gluconate is 10.31%.
Wherein each portion of the formulated mineral is required to be used with 2.33 portions of calcium citrate.
Example 3
A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; iron and zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate;
wherein the content of the retinyl palmitate in the compound vitamin is 3.08 percent, the content of the d-alpha-tocopherol acetate is 9.99 percent, and the content of the thiamine hydrochloride is 0.45 percent; the content of ferrous gluconate in the compound mineral is 36.96 percent, and the content of zinc gluconate is 13.85 percent.
Wherein each portion of the formulated mineral is required to be used with 3.33 portions of calcium citrate.
Example 4
A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; iron and zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate;
wherein the content of the retinyl palmitate in the compound vitamin is 1.92 percent, the content of the d-alpha-tocopherol acetate is 7.61 percent, and the content of the thiamine hydrochloride is 0.34 percent; the content of ferrous gluconate in the compound mineral is 13.91 percent, and the content of zinc gluconate is 8.25 percent.
Wherein each portion of the formulated mineral is required to be used with 3.33 portions of calcium citrate.
Example 5
A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; iron and zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate;
wherein the content of the retinyl palmitate in the compound vitamin is 3.52 percent, the content of the d-alpha-tocopherol acetate is 13.32 percent, and the content of the thiamine hydrochloride is 0.55 percent; the content of ferrous gluconate in the compound mineral is 44.34%, and the content of zinc gluconate is 16.62%.
Wherein each portion of formulated mineral is required to be used with 3.33 portions of calcium citrate.
Comparative example 1
A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl acetate, dl-alpha-tocopherol acetate and thiamine nitrate; iron and zinc in the compound mineral are respectively provided by ferric pyrophosphate and zinc sulfate;
wherein the content of retinyl acetate in the compound vitamin is 3.08%, the content of dl-alpha-tocopherol acetate is 9.99%, and the content of thiamine nitrate is 0.45%; the content of the iron pyrophosphate in the compound mineral is 36.96 percent, and the content of the zinc sulfate is 13.85 percent.
Wherein each portion of the formulated mineral needs to be used with 1.33 portions of calcium carbonate.
Comparative example 2
A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl acetate, dl-alpha-tocopherol acetate and thiamine nitrate; iron and zinc in the compound mineral are respectively provided by ferric pyrophosphate and zinc sulfate;
wherein the content of retinyl acetate in the compound vitamin is 3.08%, the content of dl-alpha-tocopherol acetate is 9.99%, and the content of thiamine nitrate is 0.45%; the content of ferric pyrophosphate in the compound mineral is 36.96%, and the content of zinc sulfate is 13.85%.
Wherein each portion of formulated mineral is required to be used with 2.33 parts of calcium carbonate.
Experimental example of animals
Animal experiments mainly verify that the preferable vitamin A, vitamin E and vitamin B in the scheme 1 The composition of calcium, iron and zinc has the difference with the original composition in the aspects of immune function and digestion and absorption rate, the preferred components are evaluated for enhancing the immune function and the digestion and absorption function, animal experiments are carried out to verify the composition, and support is provided for product development.
1 materials and methods
1.1 Primary reagent consumables
A BCA method protein content determination kit; rat interleukin 2 (IL-2) ELISA kit, rat interleukin 4 (IL-4) ELISA kit, rat gamma interferon (IFN-gamma) ELISA kit, rat immunoglobulin A (IgA) ELISA kit, rat immunoglobulin G (IgG) ELISA kit, and rat immunoglobulin M (IgM) ELISA kit. Nitric acid (Nitric acid 65%) was purchased from Merck, germany, and high purity water was supplied from Milli-Q Advantage ultra pure water system, acetonitrile, methanol (Fisher, USA).
1.2 Main instrumentation
An enzyme-labeling instrument: labsystems Multiskan MS (Finland); an electronic balance: BS-110S, sidoolis balance, beijing; TG16W minim high speed centrifuge; a desk centrifuge: 5424R type, eppendorf company (Germany); an electronic balance: mettler XS105DU (Switzerland); AC8 type plate washer: thermo Labsystems (finland); GNP-9080 type water-proof constant-temperature incubator; vortex instrument, water bath, tissue homogenizer.
An atomic absorption spectrometer: pinA Acle 900t, perkin Elmer company; UPLC chromatograph: accucore Vanqish series (containing high pressure binary system pump, automatic sample injector, diode array detector, fluorescence detector, sammer Feishel science and technology Co., USA.) Waters Alliance 2695 high performance liquid chromatography system (containing high pressure binary system pump, automatic sample injector, fluorescence detector and Empower chromatography data system, etc..) Mars class 6 full automatic high throughput microwave digestion extraction system (PYNN Bagan, USA), EHD-40 type adjustable electric heating furnace, chromatography column: agilent ZORBAOX SB-C18 column (250 mm x 4.6mm x 5 μm), thermo scientific Hypersil GOLD AQ column (250 mm x 4.6mm x 5 μm).
1.3 Experimental animals
SPF grade Primary weaning Male Sprague-Dawley (SD) rats, weighing 50-70 g, were purchased from the department of Experimental animals, department of medical science, beijing university, license number SCXK (Beijing) 2016-0012. All rats were kept at 25 + -2 deg.C and humidity 55 + -2% and had free access to water, alternating naturally day and night. Animal experiments obey the ethical requirements of experimental animals, and formal experiments are started by feeding the animals with a customized feed after adaptive feeding. Rats were randomly grouped into groups of 8 rats each, and were housed individually in cages and fed freely.
1.4 Experimental groups
Vitamin A, vitamin E, and vitamin B in the nutritional composition of control group 1 The iron and zinc compounds are respectively retinyl acetate, dl-alpha-tocopheryl acetate, thiamine nitrate, ferric pyrophosphate and zinc sulfate, and the calcium used in cooperation is calcium carbonate; vitamin A, vitamin E, vitamin B in the nutritional composition of the experimental group 1 The iron and zinc compounds are retinyl palmitate, d-alpha-tocopherol acetate, thiamine hydrochloride, ferrous gluconate and zinc gluconate, and the calcium is calcium citrate. The addition of each nutrient to each 10kg of feed in the control group and the experimental group is detailed in tables 1 and 2. Wherein, the content of effective components of each nutrient in the control group 1 is the same as that in the experimental group 1, and the content of effective components of each nutrient in the control group 2 is the same as that in the experimental group 2.
TABLE 1 control group with addition of nutrients to each 10kg of feed
TABLE 2 nutrient supplements per 10kg feed in the experimental group
1.5 Experimental methods
Experimental each group of rat feeds was provided by Beijing huafukang biotech co, LTD, in accordance with each group of nutrient formulations. The initial weaning rats are adaptively raised and then randomly grouped into 8 groups, and are respectively given customized sample feed to start formal experiments.
The weight of the mice and the amount of feed consumed were recorded, weighed weekly.
Each group of rats respectively take blood from orbital venous plexus at 0, 1, 2, 3, 4 and 5 weeks, each blood is taken for 1.2-1.5 mL, the rats stand for 30min after blood taking and are centrifuged for 10min at 3000r/min, and serum is taken and stored in a refrigerator at minus 80 ℃ for detection of immune factors IL-2, IL-4, IFN-gamma and immune globulin IgM, igA and IgG in the rat serum.
After the 4 th week, placing each group of rats in a metabolism cage for calcium apparent absorption rate experiment, weighing nine early spots on the first day, and supplementing 150g of corresponding sample feed; collecting feces nine times earlier the next day, and storing at-80 deg.C. Weighing and collecting the excrement two days later at nine early points, and storing the collected excrement and the collected excrement together.
Animal experiment is carried out till the end of 5 weeks, rats are anesthetized, blood is taken from heart, the rat is kept still for 30min,3000r/min and centrifuged for 10min, and blood serum is stored at the temperature of minus 80 ℃ and used for blood serum vitamin A, E and B 1 And detection of immune factors; immediately dissecting and taking the heart, the liver, the kidney, the spleen and thighbones at two sides after blood is taken, weighing and recording the heart, the liver, the kidney and the spleen, bagging the liver and the kidney, placing the liver and the kidney into an ice box, weighing and recording the thighbones at left and right, and measuring the length and the diameter record at the middle point of the thighbones by using a vernier caliper. And packaging the measured thighbone and storing the thighbone in an ice box, storing the thighbone in a refrigerator at the temperature of-80 ℃ after all experiments are finished, and analyzing and detecting Ca, fe and Zn elements by using the liver, the kidney and the bones.
1.6 detection index
1.6.1 detection of immune factors and immunoglobulins in serum
Immune factor
IL-2 is one of the earliest cytokines discovered, also known as T cell growth factor, that promotes the proliferation, induces the differentiation and apoptosis of T cells.
IL-4 is a cytokine which is secreted mainly from monocytes of activated T cell nuclei, has various biological functions such as stimulating the growth and proliferation of B cells, promoting and regulating the production of IgE, and promoting the growth and proliferation of T cells, but inhibiting the function of Th1 cells, and has a promoting effect on many inflammatory reactions.
IFN-gamma is a multifunctional active protein produced by monocytes and lymphocytes, kills antigens and tumor cells by activating phagocytes, and strengthens killing activity of NK cells by strengthening neutrophil, thereby achieving killing power to body tumor cells and causing apoptosis of the tumor cells. Therefore, the experiment comparatively evaluates the influence of the composition on the immune function of the rat by measuring the secretory content of IL-2, IL-4 and IFN-gamma in the serum of the rat.
Taking blood from orbital venous plexus of 0, 1, 2, 3, 4 and 5 weeks of rats respectively, taking 1.2-1.5 mL of blood from each rat, standing for 30min after blood taking, centrifuging for 10min at 3000r/min, taking serum, storing in a refrigerator at-80 ℃, and detecting immune factors IL-2, IL-4 and IFN-gamma in the serum by using an ELISA kit.
Immunoglobulins
Immunoglobulin refers to a globulin having the activity of an antibody or a chemical structure similar to an antibody. Immunoglobulins are a receptor on the surface of B lymphocytes, and play an important role in various cell processes such as activation and differentiation of cells. Immunoglobulins are secreted into the blood or other body fluids and are capable of binding to the corresponding antigen, which results in direct neutralization of foreign antigens or as an initial trigger for the initiation and recruitment of effector systems, such as activation of complement or mononuclear phagocyte-mediated antibody-dependent cytolysis. In the experiment, the influence of the emulsified nutrients on the immune function of the rat is contrastively evaluated by measuring the secretory contents of immunoglobulin IgM, igA and IgG in the serum of the rat.
Taking blood from orbital venous plexus of 0, 1, 2, 3, 4 and 5 weeks of each group of rats, taking 1.2-1.5 mL of blood from each rat, standing for 30min after blood taking, centrifuging for 10min at 3000r/min, taking serum to store in a refrigerator at-80 ℃, and detecting immunoglobulin IgM, igA and IgG in the serum by using an ELISA kit.
1.6.2 blood vitamins A, E and B 1 Detection of
Vitamin A, E serum sample processing method: naturally thawing the frozen serum at room temperature in a dark condition, and shaking and mixing uniformly. Taking 1ml of rat serum, placing the rat serum in a 10ml centrifuge tube, adding 3ml of a mixed solvent of methanol-acetonitrile 2:1, uniformly mixing, carrying out vortex oscillation for 30s, carrying out ultrasonic treatment for 1min, standing the rat serum for 15min at room temperature to precipitate protein, adding 4.5ml of n-hexane, carrying out vortex extraction for 1min, centrifuging the rat serum for 5min at 10000r, taking 4ml of a supernatant organic layer, placing the supernatant organic layer in a 5ml EP tube, carrying out nitrogen blow-drying at room temperature, adding 500ul of methanol into residues for redissolving, carrying out ultrasonic dissolution, and carrying out HPLC determination.
Vitamin B 1 The sample processing method comprises the following steps: mu.L of serum was taken and placed in an EP tube, 50. Mu.L of 0.5mmol/L NaOH solution was added and vortexed for 30s. Adding ethyl acetate 5mL, vortexing for 3min, centrifuging at 5000r/min at 4 ℃ for 5min, transferring 4mL of supernatant, and drying in a water bath at 37 ℃ with nitrogen. The residue was redissolved in 200. Mu.L, and 20. Mu.L was analyzed by HPLC.
1.6.3 detection of calcium, zinc and iron content in liver, kidney and bone tissue
Ca. Treating Fe and Zn samples: accurately weighing 0.3 g-0.5 g of liver, kidney and bone samples into a polytetrafluoroethylene digestion tube, adding 8mL of nitric acid, digesting the samples according to the operation steps of microwave digestion, wherein the digestion conditions are shown in Table 3. Cooling, taking out the digestion tube, and concentrating to about 1mL at 160 ℃ on an electric heating furnace. And (4) after the digestion tube is cooled, transferring the digestion solution into a 10mL volumetric flask, washing the digestion tube with a small amount of water for 2-3 times, combining the washing solutions in the volumetric flask, and fixing the volume to the scale with water. Diluting according to actual measurement requirements, mixing uniformly for later use, and detecting by using flame atomic absorption spectroscopy.
TABLE 3 microwave digestion temperature program reference conditions
| Step (ii) of | Setting temperature of | Time of temperature rise min | Constant temperature time min |
| 1 | 120 | 5 | 5 |
| 2 | 160 | 5 | 10 |
| 3 | 160 | 5 | 10 |
2 results of
2.1 serum immune factor and immunoglobulin content
TABLE 4 IL-4 (Interleukin-4) average content (pg/ml)
TABLE 5 average IFN-. Gamma.content (pg/ml)
| Group of | First week | Second week | The third week | The fourth side | Fifth week |
| Blank group | 1240.486 | 1281.798 | 1243.508 | 1283.953 | 1289.935 |
| Control group 1 | 1365.116 | 1408.751 | 1534.265 | 1486.745 | 1477.022 |
| Experimental group 1 | 1380.450 | 1429.027 | 1543.765 | 1684.630 | 1554.146 |
| Control group 2 | 1378.688 | 1440.178 | 1549.203 | 1517.846 | 1458.727 |
| Experimental group 2 | 1571.733 | 1489.588 | 1700.726 | 1794.311 | 1711.263 |
TABLE 6 IL-2 (Interleukin-2) average content (pg/ml)
| Group of | First week | Second week | The third week | The fourth side | The fifth week |
| Blank group | 1042.902 | 1069.173 | 1064.178 | 1027.153 | 1079.514 |
| Control group 1 | 1133.520 | 1167.353 | 1161.135 | 1157.116 | 1216.647 |
| Experimental group 1 | 1211.516 | 1190.189 | 1345.375 | 1401.896 | 1274.200 |
| Control group 2 | 1198.627 | 1206.942 | 1272.106 | 1256.650 | 1224.591 |
| Experimental group 2 | 1312.733 | 1352.518 | 1398.051 | 1420.932 | 1319.518 |
TABLE 7 average content (. Mu.g/ml) of Ig-A (immunoglobulin-A)
TABLE 8 Ig-G (immunoglobulin-G) average content (mg/ml)
| Group of | First week | Second week | The third week | The fourth side | The fifth week |
| Blank group | 8.500 | 8.393 | 7.928 | 9.199 | 9.275 |
| Control group 1 | 9.069 | 9.802 | 10.091 | 10.474 | 10.524 |
| Experimental group 1 | 9.936 | 10.150 | 10.426 | 10.911 | 10.485 |
| Control group 2 | 9.610 | 10.342 | 10.426 | 10.637 | 10.619 |
| Experimental group 2 | 10.147 | 10.573 | 12.357 | 11.448 | 10.732 |
TABLE 9 average content (. Mu.g/ml) of Ig-M (immunoglobulin-M)
| Group of | First week | Second week | The third week | The fourth side | Fifth week |
| Blank group | 629.669 | 638.632 | 688.756 | 770.607 | 754.908 |
| Control group 1 | 726.610 | 745.489 | 825.245 | 982.522 | 876.075 |
| Experimental group 1 | 786.849 | 799.183 | 980.335 | 1082.967 | 919.996 |
| Control group 2 | 835.514 | 828.857 | 876.077 | 1032.666 | 916.601 |
| Experimental group 2 | 848.961 | 1018.171 | 1082.076 | 1095.235 | 1061.023 |
From tables 4-9, it can be seen that the contents of the immune factors IL-2, IL-4, IFN-gamma, ig-A, ig-G and Ig-M in the serum of the experimental animals of the experimental group and the control group are gradually increased in 1-4 weeks, the peak value is reached in 4 weeks, the content of the experimental group 1 is higher than that of the control group 1, and the content of the experimental group 2 is higher than that of the control group 2; the experimental group nutrients are superior to the control group in the aspect of promoting immunity.
2.2 serum vitamin A, vitamin E, vitamin B 1 In an amount of
TABLE 10 vitamin A, vitamin E, vitamin B 1 In an amount of
As can be seen from Table 10, the serum contents of vitamin A, vitamin E and vitamin B in rats in the experimental group 1 The content of (b) is higher than that of the corresponding control group; shows that the vitamin A, the vitamin E and the vitamin B are used in the experimental group of nutrients 1 The absorption rate of the vitamin A, the vitamin E and the vitamin B is better than that of the vitamin A, the vitamin E and the vitamin B used in a control group 1 。
2.3 content of calcium, zinc and iron in liver, kidney and bone
TABLE 11 calcium content (mg/kg) in liver, kidney and bones
| Group of | Liver disease | Kidney (A) | Skeleton(s) |
| Blank group | 23.488 | 51.913 | 4550.500 |
| Control group 1 | 35.125 | 62.700 | 4874.375 |
| Experimental group 1 | 69.600 | 65.225 | 5181.250 |
| Control group 2 | 48.300 | 72.188 | 5480.625 |
| Experimental group 2 | 75.112 | 76.173 | 6244.875 |
TABLE 12 Zinc content in liver, kidney and bone (mg/kg)
| Group of | Liver disease | Kidney (A) | Skeleton(s) |
| Blank group | 19.738 | 22.938 | 99.050 |
| Control group 1 | 26.075 | 24.763 | 106.013 |
| Experimental group 1 | 26.875 | 25.063 | 108.219 |
| Control group 2 | 27.700 | 25.338 | 110.938 |
| Experimental group 2 | 27.962 | 26.075 | 116.038 |
TABLE 13 iron content in liver, kidney and bones (mg/kg)
From tables 11-13, it can be seen that the contents of calcium, zinc and iron in the liver, kidney and bone of the rats in the experimental group are all higher than those in the corresponding control group, which indicates that the contents of calcium, zinc and iron used in the nutrients in the experimental group are better than those used in the control group in terms of digestion and absorption.
In summary, the combination of retinyl palmitate, d-alpha-tocopherol acetate, thiamine hydrochloride, ferrous gluconate, zinc gluconate and calcium citrate in the nutritional composition used in the embodiment (i.e. the experimental group of the animal experiment) of the invention is obviously better than the combination of retinyl acetate, dl-alpha-tocopherol acetate, thiamine nitrate, ferrous sulfate, zinc sulfate and calcium carbonate in the currently commonly used nutritional composition (i.e. the control group of the experimental animal) in the aspect of promoting the immunity and the digestion and absorption of rats.
Application examples
The application examples of the compound vitamins and compound minerals of the specific embodiments in the infant formula milk powder are as follows, wherein the parts are weight parts.
Application example 1
The infant formula milk powder using the compound vitamins and compound minerals is prepared from the following components in parts by weight per 1000 parts of milk powder: 1740 parts of raw milk (dry matter content is 12.2%), 420 parts of desalted whey powder, 119 parts of lactose, 190 parts of edible vegetable blend oil, 23 parts of fructo-oligosaccharide powder, 10 parts of concentrated whey protein powder, 10 parts of whey protein powder, 8 parts of arachidonic acid powder, 7.5 parts of docosahexaenoic acid powder, 6 parts of calcium citrate, 3 parts of potassium chloride, 2 parts of sodium citrate, 3 parts of compound vitamin, 3 parts of compound mineral substance, 1 part of compound nutrient and 1 part of compound choline chloride; the raw materials are prepared into the final product by batching, homogenizing, sterilizing, evaporating, concentrating and spray drying.
Application example 2
Every 1000 parts of the infant formula milk powder using the compound vitamins and compound minerals is prepared from the following components in parts by weight: 1730 parts of raw milk (dry matter content is calculated by 12.2%), 420 parts of desalted whey powder, 119 parts of lactose, 190 parts of edible vegetable blend oil, 23 parts of fructo-oligosaccharide powder, 10 parts of concentrated whey protein powder, 10 parts of whey protein powder, 8 parts of arachidonic acid powder, 7.5 parts of docosahexaenoic acid powder, 6 parts of calcium citrate, 3 parts of potassium chloride, 2 parts of sodium citrate, 3.5 parts of compound vitamin, 3.5 parts of compound mineral substance, 1 part of compound nutrient and 1 part of compound choline chloride; the raw materials are prepared into the final product by batching, homogenizing, sterilizing, evaporating, concentrating and spray drying.
Application example 3
The infant formula milk powder using the compound vitamins and compound minerals is prepared from the following components in parts by weight per 1000 parts of milk powder: 1750 parts of raw milk (dry matter content is calculated by 12.2%), 420 parts of desalted whey powder, 119 parts of lactose, 190 parts of edible vegetable blend oil, 23 parts of fructo-oligosaccharide powder, 10 parts of concentrated whey protein powder, 10 parts of whey protein powder, 8 parts of arachidonic acid powder, 7.5 parts of docosahexaenoic acid powder, 6 parts of calcium citrate, 3 parts of potassium chloride, 2 parts of sodium citrate, 2.5 parts of compound vitamin, 2.5 parts of compound mineral substance, 1 part of compound nutrient and 1 part of compound choline chloride; the raw materials are prepared into the final product by batching, homogenizing, sterilizing, evaporating, concentrating and spray drying.
While the invention has been described with reference to specific embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention.
Claims (10)
1. A nutritional composition for infant formula comprises compound vitamins and compound minerals, wherein the compound vitamins comprise vitamin A, vitamin E and vitamin B 1 Respectively provided by retinyl palmitate, d-alpha-tocopherol acetate and thiamine hydrochloride; the iron and the zinc in the compound mineral are respectively provided by ferrous gluconate and zinc gluconate.
2. The nutritional composition of claim 1, wherein the compound vitamin comprises retinyl palmitate in an amount of about 1.92 to about 3.52%, d-alpha-tocopherol acetate in an amount of about 7.61 to about 13.32%, and thiamine hydrochloride in an amount of about 0.34 to about 0.55%; preferably, the vitamin complex contains retinyl palmitate about 2.09-3.32%, d-alpha-tocopherol acetate about 8.29-12.54%, and thiamine hydrochloride about 0.37-0.51%.
3. The nutritional composition of claim 1, wherein the compounded mineral has a ferrous gluconate content of about 13.91 to 44.35% and a zinc gluconate content of about 8.25 to 16.62%; preferably, the compound mineral contains ferrous gluconate about 15.13-41.76% and zinc gluconate about 8.97-15.65%.
4. The nutritional composition of claim 1, wherein the calcium is provided by calcium citrate.
5. The nutritional composition according to claim 4, wherein the weight ratio of the calcium citrate to the compound mineral is (1.33-3.33): 1.
6. Infant formula comprising a nutritional composition according to claims 1-5.
7. The infant formula of claim 6, wherein the level of vitamin complex is from about 0.1 to 1%, preferably from about 0.3 to 0.5%; the content of the compound mineral is about 0.1-1%, preferably about 0.3-0.5%.
8. Use of the nutritional composition according to any one of claims 1 to 5 for the preparation of an infant formula.
9. The use according to claim 8, wherein the content of the vitamin complex in the infant formula is about 0.1 to 1%, preferably about 0.3 to 0.5%; the content of the compound mineral is about 0.1-1%, preferably about 0.3-0.5%.
10. The use according to claim 8, wherein the vitamin complex comprises retinyl palmitate in an amount of about 1.92 to 3.52%, d-alpha-tocopheryl acetate in an amount of about 7.61 to 13.32%, thiamine hydrochloride in an amount of about 0.34 to 0.55%; preferably, the compound vitamin contains retinyl palmitate about 2.09-3.32%, d-alpha-tocopherol acetate about 8.29-12.54%, and thiamine hydrochloride about 0.37-0.51%;
wherein the content of the ferrous gluconate in the compound mineral is about 13.91 to 44.35 percent, and the content of the zinc gluconate is about 8.25 to 16.62 percent; preferably, the compound mineral contains ferrous gluconate about 15.13-41.76% and zinc gluconate about 8.97-15.65%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110356483.9A CN115153031A (en) | 2021-04-01 | 2021-04-01 | Nutritional composition for infant formula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110356483.9A CN115153031A (en) | 2021-04-01 | 2021-04-01 | Nutritional composition for infant formula |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115153031A true CN115153031A (en) | 2022-10-11 |
Family
ID=83475651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110356483.9A Pending CN115153031A (en) | 2021-04-01 | 2021-04-01 | Nutritional composition for infant formula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115153031A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023165323A1 (en) * | 2022-03-02 | 2023-09-07 | 黑龙江飞鹤乳业有限公司 | Nutritional composition, formula food product and use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108174921A (en) * | 2018-02-08 | 2018-06-19 | 呼伦贝尔双娃乳业有限公司 | A kind of organic babies ' formula milk powder |
| CN110100905A (en) * | 2019-05-17 | 2019-08-09 | 福建农林大学 | A kind of baby formula milk powder containing human milk oligosaccharides and OPO structured lipid |
| CN110638042A (en) * | 2019-11-04 | 2020-01-03 | 光明乳业股份有限公司 | Full-nutrition formula food and application thereof |
-
2021
- 2021-04-01 CN CN202110356483.9A patent/CN115153031A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108174921A (en) * | 2018-02-08 | 2018-06-19 | 呼伦贝尔双娃乳业有限公司 | A kind of organic babies ' formula milk powder |
| CN110100905A (en) * | 2019-05-17 | 2019-08-09 | 福建农林大学 | A kind of baby formula milk powder containing human milk oligosaccharides and OPO structured lipid |
| CN110638042A (en) * | 2019-11-04 | 2020-01-03 | 光明乳业股份有限公司 | Full-nutrition formula food and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 漳州师范学院化学与环境科学系无机及材料化学教研室: "食品功能成分的制备及其应用", vol. 1, 科学技术文献出版社, pages: 345 - 347 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023165323A1 (en) * | 2022-03-02 | 2023-09-07 | 黑龙江飞鹤乳业有限公司 | Nutritional composition, formula food product and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hussain et al. | Mechanistic impact of zinc deficiency in human development | |
| Xiao et al. | Effects of a tripeptide iron on iron-deficiency anemia in rats | |
| Li et al. | Effect of different sources and levels of iron in the diet of sows on iron status in neonatal pigs | |
| CN111990462A (en) | Infant formula containing protein composition and preparation method thereof | |
| Lien et al. | Chromium picolinate reduces laying hen serum and egg yolk cholesterol | |
| Kachuee et al. | The effect of dietary organic and inorganic selenium supplementation on serum Se, Cu, Fe and Zn status during the late pregnancy in Merghoz goats and their kids | |
| Teama et al. | Physiological and biochemical response to Omega-3 plus as a dietary supplement to growing goats under hot summer conditions | |
| CA2508180C (en) | Dimetalhydroxy malates | |
| Caballero Valcárcel et al. | Iron bioavailability of four iron sources used to fortify infant cereals, using anemic weaning pigs as a model | |
| Stepanova et al. | Peculiarities of mineral metabolism of Holstein heifers’ diet supplemented with copper Nanopowders | |
| CN115153031A (en) | Nutritional composition for infant formula | |
| Zlotkin et al. | Demonstrating zinc and iron bioavailability from intrinsically labeled microencapsulated ferrous fumarate and zinc gluconate Sprinkles in young children | |
| Wang et al. | Effects of delta-aminolevulinic acid and vitamin C supplementation on feed intake, backfat, and iron status in sows1 | |
| Kawashima et al. | Bioavailability of cobalt sources for ruminants. 2. Estimation of the relative value of reagent grade and feed grade cobalt sources from tissue cobalt accumulation and vitamin B12 concentrations | |
| Ashrafi et al. | Effect of Organic Selenium Supplementation on the Antioxidant Status, Immune Response, and the Relative Expression of IL-2 and IFN-γ Genes in Ewes During the Hot Season | |
| CN117481199A (en) | Premature/low birth weight infant food for promoting growth and development, and preparation method and application thereof | |
| WO2023165323A1 (en) | Nutritional composition, formula food product and use | |
| Malhotra et al. | A recent paradigm on iron absorption, prevalence, and emerging dietary approaches to eradicate iron deficiency | |
| Olivares et al. | Copper and zinc interactions in anemia: a public health perspective | |
| CN101401649A (en) | Composition capable of reinforcing organism phylactic power | |
| Pirman et al. | Fe bioavailability from Fe-enriched yeast biomass in growing rats | |
| Milanović et al. | The influence of organic and inorganic Fe supplementation on red blood picture, immune response and quantity of iron in organs of broiler chickens | |
| RU2591993C1 (en) | Agent for stimulating metabolic processes, increasing productivity and safety of animals and birds | |
| RU2698120C1 (en) | Method for alimentary osteodystrophy treatment and prevention in lactating cows | |
| Williams et al. | Effects of feeding increasing levels of iron from iron sulfate or iron carbonate on nursery pig growth performance and hematological criteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |